Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.

Published byTeija Jaana Penttilä Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients."— Presentation transcript:

1 Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients with untreated multiple sclerosis (MS), and 11 patients with fingolimod-treated MS were briefly stimulated ex vivo with lipopolysaccharide (LPS). Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients with untreated multiple sclerosis (MS), and 11 patients with fingolimod-treated MS were briefly stimulated ex vivo with lipopolysaccharide (LPS). Monocytes were gated by forward vs side scatterplot and CD14-positive staining. Gate on viable (7-AAD negative) cells was then applied. Monocyte activation was monitored by staining for the 2 surface markers CD25 and CD150. Thresholds were set on relative isotype controls. (A) Frequency of CD25-positive (upper graph) and CD150-positive (lower graph) monocytes cultured ex vivo with 100 ng/mL LPS; each dot represents a single participant; black bars represent mean values for each group. (B) CD25 (upper) and CD150 (lower) stainings in cultures stimulated with 600 pg/mL LPS from a representative healthy control (left), a patient with untreated MS (middle), and a patient with fingolimod-treated MS (right). (C) Frequency of CD25 and CD150 positive monocytes at increasing LPS concentrations. Dose response curves are shown for each participant. Right panels show the means for each group. *p < 0.05; ***p < FSC = forward scatter. Marco Di Dario et al. Neurol Neuroimmunol Neuroinflamm 2015;2:e157 © 2015 American Academy of Neurology

Download ppt "Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients."

Similar presentations

Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor  Preston E. Bratcher, Steven M. Rowe, Ginger.

Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor  Preston E. Bratcher, Steven M. Rowe, Ginger.
Characterization of a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cells by Yohei Iwata, Takashi Matsushita, Mayuka.

Characterization of a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cells by Yohei Iwata, Takashi Matsushita, Mayuka.
Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
Figure 3 B-cell amount and the frequency of various B-cell subtypes are differentially affected by FTY or DMF treatment B-cell amount and the frequency.

Figure 3 B-cell amount and the frequency of various B-cell subtypes are differentially affected by FTY or DMF treatment B-cell amount and the frequency.
Figure 3 Antibodies to MOG using different secondary antibodies: Anti-human IgG (H + L), IgG1, or IgM(A) Comparison of binding to full-length myelin oligodendrocyte.

Figure 3 Antibodies to MOG using different secondary antibodies: Anti-human IgG (H + L), IgG1, or IgM(A) Comparison of binding to full-length myelin oligodendrocyte.
Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.

Figure 3 Immunohistochemical analyses of positive and negative Epstein-Barr virus (EBV) control tissues using immunostaining Immunohistochemical analyses.
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 3 JCV index changes in JCV+ patients

Figure 3 JCV index changes in JCV+ patients
Figure 3 Decreased AHI1 in human CD4+ T cells is associated with decreased proliferation and increased IFNγ production Decreased AHI1 in human CD4+ T cells.

Figure 3 Decreased AHI1 in human CD4+ T cells is associated with decreased proliferation and increased IFNγ production Decreased AHI1 in human CD4+ T cells.
Figure 2 The frequency of helper T cells (Th) within CD4+ population and TCRγδ within CD3+ cells is affected by FTY and DMF treatment The frequency of.

Figure 2 The frequency of helper T cells (Th) within CD4+ population and TCRγδ within CD3+ cells is affected by FTY and DMF treatment The frequency of.
Figure 2 Brain-infiltrating immune cells mainly consist of CD8+ memory T cells Immunofluorescence staining of brain-infiltrating immune cells. Brain-infiltrating.

Figure 2 Brain-infiltrating immune cells mainly consist of CD8+ memory T cells Immunofluorescence staining of brain-infiltrating immune cells. Brain-infiltrating.
Figure 1 Effect of DMF therapy on T cell subsets

Figure 1 Effect of DMF therapy on T cell subsets
Kathleen R. Bartemes, BA, Gail M. Kephart, BS, Stephanie J

Kathleen R. Bartemes, BA, Gail M. Kephart, BS, Stephanie J
Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.

Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.
Figure 2 Alemtuzumab-induced changes in the dendritic cell compartment

Figure 2 Alemtuzumab-induced changes in the dendritic cell compartment
Figure 1 The abundance of CD3+ T cells and their subtypes are significantly affected by FTY and DMF treatment The abundance of CD3+ T cells and their subtypes.

Figure 1 The abundance of CD3+ T cells and their subtypes are significantly affected by FTY and DMF treatment The abundance of CD3+ T cells and their subtypes.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)
Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.

Figure 1 Peripheral blood leukocyte subset counts during dimethyl fumarate treatmentComplete blood cell counts were obtained at baseline (n = 34) and at.
Figure 2. ROC curves for different group comparisons

Figure 2. ROC curves for different group comparisons

Similar presentations

Ads by Google